XTLB vs. HUGE, PIRS, EDSA, RDHL, PPBT, KPRX, TNXP, ERNA, NRSN, and IMNN
Should you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include FSD Pharma (HUGE), Pieris Pharmaceuticals (PIRS), Edesa Biotech (EDSA), RedHill Biopharma (RDHL), Purple Biotech (PPBT), Kiora Pharmaceuticals (KPRX), Tonix Pharmaceuticals (TNXP), Eterna Therapeutics (ERNA), NeuroSense Therapeutics (NRSN), and Imunon (IMNN). These companies are all part of the "pharmaceutical preparations" industry.
XTL Biopharmaceuticals (NASDAQ:XTLB) and FSD Pharma (NASDAQ:HUGE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.
XTL Biopharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.
XTL Biopharmaceuticals received 79 more outperform votes than FSD Pharma when rated by MarketBeat users. Likewise, 71.82% of users gave XTL Biopharmaceuticals an outperform vote while only 0.00% of users gave FSD Pharma an outperform vote.
4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 1.2% of FSD Pharma shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 8.5% of FSD Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, FSD Pharma had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for FSD Pharma and 2 mentions for XTL Biopharmaceuticals. FSD Pharma's average media sentiment score of 0.50 beat XTL Biopharmaceuticals' score of 0.00 indicating that FSD Pharma is being referred to more favorably in the news media.
FSD Pharma's return on equity of -70.35% beat XTL Biopharmaceuticals' return on equity.
Summary
XTL Biopharmaceuticals beats FSD Pharma on 6 of the 10 factors compared between the two stocks.
Get XTL Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
XTL Biopharmaceuticals Competitors List
Related Companies and Tools
